According to a recent LinkedIn post from RECEPTORAI, the company plans to attend the AACR Annual Meeting 2026 in San Diego from April 17–22. The post notes that CEO and founder Alan Nafiev, Ph.D., Head of Business Development Askar Kuchumov, Ph.D., and External Partnership Representative Andrew Lozoniuk are expected to participate.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The company’s LinkedIn post highlights an interest in meetings with potential partners to discuss oncology drug discovery challenges. The post suggests a focus on areas spanning hit discovery and multiparameter optimization across small molecules, peptides, and protein–protein interaction programs.
For investors, this planned presence at AACR indicates an effort to deepen engagement with the oncology research and pharmaceutical ecosystem. Increased visibility at a major cancer research forum could support RECEPTORAI’s business development pipeline and may open opportunities for collaborations or licensing discussions over the medium term.
The emphasis on multiparameter optimization and diverse therapeutic modalities may position the company within high-value niches of AI-enabled and computational drug discovery. If partnership discussions at AACR translate into formal agreements, this could enhance revenue visibility and strengthen RECEPTORAI’s competitive standing in oncology-focused platforms.